

OTS: 60-41,530

JPRS: 5778

10 October 1960

MODIFICATIONS OF THE PROTEINS, LIPOPROTEIDS AND
GLUCOPROTEIDS IN THE BLOOD OF PATIENTS SUFFERING
FROM DIABETES MELLITUS

T

By M. Sheykman

- USSR -

**Reproduced From
Best Available Copy**

DISTRIBUTION STATEMENT A
Approved for Public Release
Distribution Unlimited

20000821 142

Distributed by:

OFFICE OF TECHNICAL SERVICES
U. S. DEPARTMENT OF COMMERCE
WASHINGTON 25, D. C.

U. S. JOINT PUBLICATIONS RESEARCH SERVICE
205 EAST 42nd STREET, SUITE 300
NEW YORK 17, N. Y.

DTIC QUALITY INSPECTED

**Reproduced From
Best Available Copy**

JPRS: 5778

DSO: 4727-N

MODIFICATIONS OF THE PROTEINS, LIPOPROTEIDS, AND
GLUCOPROTEIDS IN THE BLOOD OF PATIENTS SUFFERING
FROM DIABETES MELLITUS

Following is the translation of an article by
M. B. Sheykman (Moscow) entitled "Izmeneniya
Belkov, Lipoproteidov i Glyukoproteidov Krovi
u Bol'nykh Sakharnym Diabetom" (English version
above) in Klinicheskaya Meditsina (Clinical
Medicine), Vol. 38, No. 7, July 60, pages 36-43.⁷

From the Chair of Endocrinology (Head -- Honored
Worker of Science Prof. N. A. Shereshevskiy) of
the Central Institute for the Advanced Training
of Physicians (Dir. -- M. D. Kovrygina) at the
Base of the Clinical Order of Lenin Hospital
imeni S. P. Botkin (Chief Physician -- Prof.
A. N. Shabanov)

The physiological importance of the simple and complex
proteins and proteids of plasma is very great. The successes
achieved in recent years in the physicochemical study of
proteins (by electrophoresis, ultracentrifugation, etc.) has
made it possible to undertake a more thorough study of the
protein-proteid composition of the blood under various patho-
logical conditions. The accumulated observations have made
it possible to speak of blood protein changes characteristic
of various diseases, and have aided substantially in the
physiopathological and clinical characterization of some of
them. The changes in proteins and proteids (lipoproteids
and glucoproteids) of the blood plasma, which depend on the
character and degree of impairment of metabolic processes,
have definite diagnostic and differential-diagnostic and great
prognostic value in a number of diseases (Antweiler, Wuhrman
and Wunderly, Riva, Emmrich, Girard).

In diabetes mellitus considerable modification occurs
in the metabolism of simple and complex proteins, as a result
of impairment of the neuroendocrine regulation of metabolic
processes. A change in the protein-proteid blood composition
is one of the manifestations of these metabolic disturbances.
The origin and character of these changes have not yet been

studied sufficiently. The deficit of insulin and of the lipotropic factor of the pancreas, as well as the impaired functioning of the hypophysis, suprarenal and genital glands, are important factors in bringing about these changes. It has been elicited experimentally that insulin doses which contribute to protein synthesis exceed three to five fold times the amount of insulin needed for the maintenance of normal glycemia (Wenderoth). Considerable modifications of the protein-proteid composition of blood were elicited in experimental diabetes (Lewis, Christiansson, Peterson and Beatty), in hypophysectomy, adrenalectomy, and administration of sexual hormones as well as of hormones of the anterior hypophyseal lobe and the adrenal cortex (Bernasconi, Del Vecchio, et al., Aschkenasy, Furman and Howard, Berezin and Studnitz, bellieni).

In recent years there have appeared in the foreign literature a number of works devoted to the study of the protein-proteid blood composition in patients with diabetes mellitus. The basic changes in blood serum proteins in diabetic patients were manifested in the form of hypoalbuminemia and hyperglobulinemia. Different changes in the globulin fractions were elicited (the greatest changes were elicited by various authors in alpha₂-globulin, in beta-globulin, simultaneously in alpha₂- and beta-globulins or in gamma-globulin), which resulted in contradictory data in the literature (Beckman, Bogdanovich, et al; Ralli, et al; Scheurlen, de-Petra and Princi; Melingoff, et al; Lewis, et al; Lederer, et al; Schertenleib, et al; Introzzi, et al.). There is no unanimous opinion as to the character of the changes of blood lipoproteids in diabetes. The majority of authors noted in diabetic patients, especially in the presence of atherosclerosis, the predominance in the blood of beta-lipoproteid richer in cholesterol and more labile (lipoproteid of the Sf-10-20 Hoffman ultracentrifugation class; Baker, et al.; Lowy and Barach; Feruglio and Rimini; Polosa and Motta; Azerad, et al; Tolomelli, et al.; Weicker and Ley; Kuguda, et al; Vannini, et al.). A number of authors noted a considerably increased number of glucoproteids in the blood of diabetic patients (hexoses bound with protein, glucosamine, etc.), especially in the alpha₂- fraction. These changes depend on the duration of the diabetes and the degree of degenerative changes in the blood vessels (Mohnike, Jannert, et al.; Bergstermann, Jacobs, Galletti, et al.; Jilliland, et al.; Nielsen and Poulsen; Lerman, et al.; Andriani, et al; Basteni, et al.; Candor, Nervi and de Petra; Orabona, et al.).

Taking into account the experimental data, which attest to the indubitable pathogenic significance of the impairment of the metabolism of simple and complex proteins (lipoproteids

and glucoproteids) in the development of atherosclerosis (works of N. N. Anichkov and his school; Antonini and Salvini, et al.), a number of authors contend that there exist predisposing conditions in the organisms of a diabetic patient for comparatively early and frequent development of atherosclerosis. Dickenson, as well as Wenderoth and other authors, relate the development of vascular complications in diabetes, including atherosclerosis, to a chronic protein deficiency of the organism resulting from increased neoglucogenesis. N. N. Anichkov attributes considerable importance in the development of vascular complications in diabetes to dyslipoproteinemia and hypercholesterolemia; at the same time Mohnike, as well as Introzzi, attaches considerable importance to the disturbance of glucoprotein metabolism. We must note that in atherosclerotic patients without diabetes, the changes in the blood protein composition are similar, to a great extent, to the changes observed in diabetes mellitus (M. V. Bavina, V. M. Baytsev, P. Ye. Lukomskiy, M. M. Pokhno, Antonini and Salvini, Raynaud, et al., Foigg and Schrader, Barr, Rass, et al.).

The problems of the pathogenesis of vascular complications in diabetic patients, as well as the problems of pathogenesis of atherosclerosis, are incompletely clarified and require further thorough study. Apparently, in the development of the vascular complications of diabetes, atherosclerosis in particular, a number of factors are of pathogenic significance, in particular the metabolic disorders which develop in diabetes. Of undoubted pathogenic significance are the metabolic disturbances which induce changes in the protein-protein blood composition and hypercholesterolemia. The vascular changes in diabetic patients are the results of complex metabolic disturbances in the vascular walls which are infiltrated by protein-lipid and protein-polysaccharide components of plasma (N. N. Anichkov, Mohnike, Antonini and Salvini).

Degenerative vascular changes, which are observed in nearly 70 percent of the diabetic patients, are considered at present to be the basic cause of death for diabetics (V. M. Kogan-Yasny). The statistics of recent years point to the high and constantly increasing percentage of mortality of diabetic patients from vascular causes and a corresponding reduction of the rate of mortality from diabetic coma (V. M. Kogan-Yasny, Joslin, Warren and Le Compte, Danovskiy, Kaeding, Boller). The diabetic patients die, according to the data of pathological-anatomical studies carried out during the past 20-25 years, mostly from the impairment of circulation in the cardiac blood vessels, kidneys, brain and lower

extremities (V. M. Kogan-Yasnyy, Joslin, Boller). Atherosclerosis develops in diabetes mellitus patients at an earlier age, and a number of authors connect the frequency and gravity of atherosclerosis in these patients with the duration of the diabetic condition (N. N. Anichkov, V. M. Kogan-Yasnyy, Matthews, Paschkis, et al., Bryfogle and Bradley); this statement has been disputed by some authors (Boas, Moschovitz, E. G. Moscovitch). Skoudy and other researchers think that an adequate therapy started promptly is the basic factor in preventing early development of vascular complications in diabetic patients.

In certain clinical forms of diabetes mellitus a good therapeutic effect was obtained with oral administration of hypoglycemic sulfanilamide preparations such as nadisan, rastinon, etc. (Bertram, et al., Boulin, Bender, et al., N. A. Shereshevskiy). At present the mechanism and character of effect of these preparations on the metabolic processes of the organism still need to be fully clarified. Kach observed impairment of fat metabolism and development of obesity in patients who had been given sulfanilamide preparations (S. M. Leytes). There are contradictory data in the work which has appeared during the past two to three years in the foreign literature on the effect of sulfanilamide preparations on the protein-proteid composition of the blood of diabetic patients: some authors note aggravation of dysproteinemia while others do not corroborate this conclusion (Chatagnon and Chatagnon, Kaeding, Muting, Kuhne, Galleti, et al., V Vanini, et al.).

Taking into account the presence of contradictory data in the foreign literature, the absence of analogous studies in the Soviet literature, and the great scientific and practical importance of this problem, we carried out an investigation of the protein-proteid composition of the blood serum in 114 diabetic patients between the ages of 17 and 76 years, who had had the disease from one or two months -- up to 33 years, without or with atherosclerotic phenomena, and who received insulin therapy and sulfanilamide preparations. Dynamic studies were carried out on 88 patients. Blood for examination was obtained in the morning on an empty stomach. Total protein was determined by the refractometric method. Fractionation of proteins and proteids of the blood serum was carried out by paper electrophoresis. The electrophoregrams were stained for protein fractions with an acid blue-black dye for lipoproteids with sudan black "B," and those for glucoproteids with the Schiff reagent (according to Rushkovskiy). Hexose, bound with the serum proteins, was determined by the method of Jannell et al. The data on the protein-

proteid composition of the blood, obtained by us, were compared with the clinical picture, with the dynamics of the disease, as well as with the results of other studies. The control group consisted of 59 normally healthy individuals between 20 and 50 years old.

The study of the electrophoregrams of the healthy individuals enabled us to establish the following average norms of the content of protein lipoproteid and glucoproteid fractions in the blood serum: albumins, 60.25%; globulin fractions: α_1 4.03%, α_2 7.9%; beta 70.95%; glucoproteids: albumins + α_1 23.20%; α_2 36.64%; beta 28.95%; gamma 11.21% (Table 1). The total blood serum protein was 7.58 gm-% (6-9.04 gm%); hexoses bound with blood serum proteins were 113 mg-% (86-139 mg-%). The average figures for the contents of proteins and proteids of the blood serum in healthy individuals, as obtained by us, coincide with the data in the literature (Bogdanovich, et al., Scheurlen, Grassman and Hanning, Coive, P. Ye. Lukomskiy, Rushkovskiy, et al.).

The diabetic patients were divided into two groups. The first group was composed of 36 patients with uncomplicated diabetes mellitus, (i.e., patients who had given no clinical evidence of atherosclerosis on examination). The other group consisted of 78 diabetic patients with definite clinical symptoms of atherosclerosis of the aorta, cardiac vessels, brain, eye fundus, and lower extremities, which were confirmed via electrocardiographic and oscillographic examinations and ophthalmoscopy of the eye fundus. The second group of patients, which included diabetics and atherosclerotics, was characterized by a higher average age and longer duration of the disease as compared to the first group. In view of the difficulty of determining accurately in a number of cases the sequence of development of diabetes and atherosclerosis, and in view of the mention in the literature of the possibility of an independent development of these two diseases (Boas; Moschowitz; E. G. Moskovich), we found it expedient, for lack of a sufficiently reliable criterion, to divide the patients into subgroups of cases of atherosclerosis as a complication of diabetes or as a concomitant disease. Patients who during the investigation manifested other diseases accompanied by changes in the protein-proteid composition of the blood serum (infectious diseases, diseases of the thyroid, malignant tumors, etc.) were not included in this study. The studies were conducted under clinical conditions. Dynamic study of the protein-proteid blood composition was carried out on 88 patients (from two to nine times on each patient); in some patients the protein composition of the blood was investigated upon the patients second admission.

Table 1

Protein, lipoproteid and glucoproteid fractions of blood serum in healthy individuals, uncomplicated diabetic patients, and diabetic patients with atherosclerosis (mean indices).

Protein-proteids		Healthy Individuals	Patients with uncomplicated diabetes mel- litus	Patients with dia- betes and athero- sclerosis
		M \pm $\sigma^{(1)}$	M \pm σ	M \pm σ
Proteins	Albumins	60.25 \pm 4.14	56.11 \pm 3.46	47 \pm 3.18
	Globulines: alpha ₁	4.03 \pm 1.09	3.44 \pm 0.84	3.8 \pm 0.63
	" alpha ₂	7.90 \pm 1.38	10.7 \pm 2.15	11.48 \pm 1.64
	" beta	11.81 \pm 1.44	12.85 \pm 1.7	16.91 \pm 2.82
	" gamma	16.01 \pm 2.05	16.9 \pm 1.97	20.81 \pm 2.14
Lipoproteids:	alpha	29.05 \pm 2.81	197.84 \pm .38	15.11 \pm 8.2
	beta	70.95 \pm 2.81	80.16 \pm 7.38	84.89 \pm 8.2
Glucoproteids	Albumins + alpha ₁	23.2 \pm 3.16	11.41 \pm 2.97	8.62 \pm 2.51
	" alpha ₂	36.64 \pm 4.92	49.83 \pm 5.04	58.52 \pm 4.74
	" beta	28.95 \pm 3.46	30.25 \pm 4.62	27 \pm 3.17
	" gamma	11.21 \pm 2.94	8.51 \pm 2.56	5.86 \pm 1.97

(1) M - arithmetical mean; σ - r.m.s. deviation.

to the clinic, six to 17 months after the first study.

In comparing the data on the protein-proteid blood composition in healthy individuals and in diabetic patients, one can observe in the latter the presence of dysproteinemia, dyslipoproteinemia and dysglucoproteinemia. These changes are more pronounced in patients suffering from diabetes and atherosclerosis. In analyzing the results of studies carried out on 36 diabetic patients with no atherosclerosis, one can observe an increase in alpha₂-globulin reaching in some cases 12.8 to 13.6%, an increase in beta-lipoproteins of at most 91-94.6%, and a marked increase in alpha₂-glucoprotein (up to 57-60.5%) in several patients. The mean content of hexoses bound with proteins was 127 mg-%; the highest contents in this group of patients were 149 to 152 mg-%. The total blood cholesterol (according to Blur) in patients of this group exceeded normal figures, reaching 300 mg-%; the mean figure for this group was 214 mg-%.

Daily, for three to six days, the protein-proteid blood content of 14 patients of this group was measured by paper electrophoresis and the data showed that changes in the proteins, lipoproteins and glucoproteins of the blood serum had no constant character. During the period of investigation fluctuations were observed in the protein-proteid blood composition of the patients. Most constant was the increase in alpha₂-globulin and alpha₂-glucoprotein. A correlation was observed between the seriousness of the diabetic condition and the protein-proteid composition of the blood. In comparing the results of studies on patients of this group, who varied as to the seriousness of their condition, we note considerably greater deviations from normal in patients in whom the disease had progressed further. Thus, in seven patients of this group with comparatively mild diabetes, during the period of compensation the content of albumin averaged 59.2%, alpha₂-globulin 8.3%, beta-lipoproteins 76.9%, and alpha₂-glucoproteins 44.1%, whereas in eight patients of the same group with more severe diabetes (higher glycemia, glucosuria, acetonuria) the mean content of albumin 51.3%, alpha-globulin 10.8%, beta-lipoprotein 81.8%, alpha₂-glucoprotein 55.6%. These data indicate the presence of more serious disturbances of protein metabolism in patients with a more severe diabetes.

In diabetic patients with marked atherosclerotic manifestations there are observed more pronounced dysproteinemia, dyslipoproteinemia and dysglucoproteinemia than in patients with simple diabetes (see Table 1). Hypoalbuminemia, more pronounced in patients of this group, reached 34 to 37.4% in some cases. The globulin content was increased, mainly in the

beta and alpha₂ fractions. The percentage of beta-lipoproteid was considerably increased, reaching in some patients 98.5%. Dysglucoproteidemia was more pronounced. The content of hexoses bound with proteins in some patients reached 200 mg-% (168 mg-% on the average), and hypercholesterinemia ranged up to 380 to 450 mg-% (249 mg-% on the average).

Daily determinations of the protein-proteid content of the blood by paper electrophoresis, conducted on 31 patients of the second group for a period of three to six days, showed individual changes more stable than the changes in patients of the first group. The most constant changes, which are characteristic for patients suffering from diabetes with atherosclerosis, are increases in beta-globulin, beta-lipoproteid and alpha₂-glucoproteid. The protein-proteid changes in the blood depend on the severity of the atherosclerotic changes in the patients. Thus, in 14 patients with a mild form of atherosclerosis the mean contents were: albumin 50.1%, beta-globulin 12.8%, beta-lipoproteid 31.7%, alpha₂-glucoproteid 51.6%, and hexoses bound with serum proteins 143 mg%. In 12 patients with atherosclerotic vascular changes that were clinically more pronounced (patients who had a history of a myocardial infarct, or cerebral hemorrhage, or marked vascular changes in the lower extremities), the average quantities were: albumin 44.2%, beta-globulin 17.3%, beta-lipoproteid 35.2%, alpha₂-glucoproteid 58.5%, hexoses bound to protein 189 mg%. The content of total blood serum proteins in both groups varied within normal limits (the average figure for the first group was 7.25 gm-%, that for the second, 7.41 gm-%).

Dynamic studies of the protein-proteid composition of blood were carried out on 47 patients treated with insulin, and on 41 patients treated with sulfanilamide preparations. The insulin therapy was carried out on 17 diabetic patients who had no atherosclerosis, and on 30 patients with clinically pronounced atherosclerosis. Sulfanilamide preparations were administered to 10 nonatherosclerotic patients and to 31 diabetic and atherosclerotic patients. In patients with uncomplicated diabetes who had been on a limited carbohydrate diet with insulin therapy as well as with sulfanilamide treatment there occurred definite normalization of the blood protein composition (Table 2). Normalization of the protein formula in patients with uncomplicated diabetes with insulin therapy was observed in seven cases, while with sulfanilamide treatments normalization occurred in three cases; discernible changes in the blood protein composition with a higher or lower approximation to normal figures (increase in albumin content, decrease in alpha₂-globulin, beta-lipoproteid and alpha₂-glucoproteid levels) -- correspondingly in

Table 2

Content of separate fractions of lipoproteids and glucoproteids of the blood serum of diabetic patients treated with insulin and sulfanilamide preparations

Protein-proteids	Patients treated with insulin			
	Diabetes without atherosclerosis		Diabetes with atherosclerosis	
	At Admis- sion	At dis- charge	At admis- sion	At dis- charge
	M ± σ*	M ± σ*	M ± σ*	M ± σ*
Content of protein-proteids in percent (average figures)				
Albumin.....	56.27±3.11	60.16±2.87	50.33±4.72	56.08±1.97
alpha ₂ -globulin.....	9.7 ±2.17	8.04±1.29	10.81±1.38	10.9 ±1.66
beta-globulin.....	12±1.79	11.25±2.04	15.17±1.38	13.8 ±1.57
beta-lipoprotein.....	80.45±6.54	74.84±5.8	83.5 ±7.06	76.47±4.98
alpha ₂ -glucoprotein.....	45.17±5.38	40.05±6	53.65±4.71	53.14±3.99

Table 2 continued from page 27

Patients treated with sulfanilamide preparations		Diabetes without atherosclerosis		Diabetes with atherosclerosis	
At admission	At discharge	At admission	At discharge	M ± σ	M ± σ
M ± σ	M ± σ	M ± σ	M ± σ	M ± σ	M ± σ
Content of protein proteins in percent (average figures)					
Albumin.....	58.1 ± 2.54	59.85 ± 4.07	48.72 ± 2.38	53.98 ± 2.6	
alpha ₂ -globulin.....	9.56 ± 2.05	8.23 ± 1.7	9.99 ± 1.94	10.77 ± 2.58	
beta-globulin.....	11.25 ± 2.96	12.78 ± 3.18	14.72 ± 3.01	15.1 ± 2.54	
beta-lipoprotein.....	79.09 ± 8.22	77.31 ± 8.02	81.22 ± 9.1	81.48 ± 7.93	
alpha ₂ -glucoprotein.....	43.81 ± 4.78	41.68 ± 5.84	52.9 ± 5.04	54.26 ± 6.23	

eight out of six patient /sic/⁷ The protein-proteid composition of the blood remained unchanged in two discharged patients treated with insulin, and in one patient who was taking nadisan. Good therapeutic effects upon administration of insulin or sulfanilamide preparations (decrease in glucemia and glucosuria, disappearance of acetonuria, and improvement of the general condition were accompanied, as a rule, by greater or lesser normalization of protein blood indices.

In diabetic patients with clinically marked atherosclerosis, normalization of protein-proteid composition of the blood in insulin therapy was noted in four cases only; approximation of protein blood indices to normal figures occurred in 15 cases; no changes were noted in 11 cases. In patients who had been given sulfanilamide preparations, normalization of protein blood composition was not observed in a single patient, approximate normalization was observed in 12 patients; no change in the protein-proteid composition of the blood was found in 19 patients. Lack of normalization of the protein-proteid blood composition was noted in diabetic patients with more pronounced atherosclerotic vascular changes. In this subgroup of patients, even at a certain diminution of glycemia and glucosuria, no tendency was observed toward normalization of the protein blood composition, which speaks for a more pronounced impairment of the protein metabolism and more permanent and stable changes in the protein composition of the blood. In five patients in whom nadisan administration was not accompanied by a good therapeutic effect (subjective data and the sugar level in the blood and urine), some electrophoregrams showed, under dynamic investigation, an increase of dysproteinemia (hypoalbuminemia and increase of beta - and gamma-globulins).

Conclusions

1. In diabetes mellitus patients changes occur in the protein-proteid composition of the blood which are manifested as dysproteinemia, dyslipoproteidemia and dysglucoproteidemia, as the result of impairment of neuroendocrine regulation of metabolic progresses. These changes depend on the seriousness of the diabetic condition, on the presence and extent of atherosclerosis and on the therapy employed.
2. In uncomplicated diabetes there is manifested an increase of alpha₂-globulin, beta-lipoproteid and alpha₂-glucoproteid. In diabetic patients with pronounced symptoms of atherosclerosis there is manifested considerable hypoalbuminemia, increase of globulin fractions (mainly at the

expense of α_2 -, beta and, to a lesser extent, gamma-globulins) as well as a stable increase in the content of beta-lipoproteid and α_2 -glucoproteids.

3. The total protein content of the blood serum in patients suffering from uncomplicated diabetes and atherosclerosis was within normal limits. The level of hexoses bound with proteins and hypercholesterinemia proved to be higher in patients suffering from diabetes and atherosclerosis!

4. The attainment of a state of compensation in diabetes by means of complex therapy (diet, insulin, sulfanilamide, preparations) is accompanied frequently by approximate or in a number of cases complete normalization of the protein blood content. In 19 out of 31 patients with pronounced atherosclerotic changes, the use of sulfanilamide preparations produced no discernible tendency toward normalization of the protein composition of the blood.

5. The data on the protein-proteid composition of the blood in diabetic patients has important prognostic value and can be utilized for the control of treatments, which is particularly important in the use of the new sulfanilamide preparations. The results of study of lipoproteids and glucoproteids have definite diagnostic value in the elicitation of vascular affections (considerable and stable increase of beta-lipoproteid, α_2 -glucoproteid, and hexoses bound with proteins).

Bibliography

1. Anichkov, N. N., In the book: Atherosclerosis and Coronary Insufficiency. Moscow, 1956, page 3.
2. Bavina, M. V., Melikova, M. Yu., Ibid., page 143.
3. Zaytsev, V. M., Klinicheskaya Meditsina (Clinical Medicine), 1957, No. 5, page 124.
4. Kogan-Yashnyy, V. M., The Diabetic Disease. Moscow, 1957, page 105.
5. Leytes, S. M., Problemy Endokrinologii i Gormonoterapii (Problems of Endocrinology and Hormonotherapy), 1958, No. 6, page 114.
6. Lukomskiy, P. Ye., Klinicheskaya Meditsina, 1957, No. 8, page 82.
7. Moskovich, E. G., Ibid., 1958, No. 10, page 76.
8. Pokhno, M. M., Works of the Odessa Medical Institute. Odessa, 1958, Vol. 3, page 134.
9. Shereshevskiy, N. A., Klinicheskaya Meditsina, 1957, No. 9, page 61.
10. Andreani D. V. a. oth., Folia endocrinol., 1956, vol. 9,

page 13.

11. Andreani D. V., Gray O., Clin. Chim. acta, 1956, vol. 1, page 7.
12. Antonini F. M., Salvini L. B. kh. Symposium über arterio-sclerose. Stuttgart, 1957, S. 209.
13. Antweiler H., Die quantitative Electrophorese in der Medizin. Berlin, 1957.
14. Aschkenasy A., J. Physiol., 1957, vol. 49, page 16.
15. Azerad E. a. oth., Presse med., 1958, vol. 66, page 995.
16. Wittenhagen G., Creutzfeld W. a. oth., Disch. med. Wschr., 1956, Bd. 81, S. 887.
17. Barr D., Russ E., Eder H., Am. J. Med., 1951, vol. 11, page 480.
18. Bastenie P. a. oth., Acta med. scandinav., 1958, vol. 160, page 205.
19. Beckman W., Arztl. Wschr., 1953, Bd. 8, S. 928.
20. Baker R. a. oth., Quart. J. Med., 1955, vol. 24, page 295.
21. Bellieni G. a. oth., Giorn. mal. infett., 1955, vol. 7, page 521.
22. Bergstermann H., Ergebni. inn. Med. u. Kinderheilk., 1956, Bd. 7, S. 17.
23. Berezin D., Studnitz W., Acta endocrinol., 1957, vol. 25, page 427.
24. Bernasconi C., Ibid., 1956, vol. 23, page 184.
25. Bertram F., Bendfeldt E., Otto H., Dtsch. med. Wschr., 1955, Bd. 80, S. 1455.
26. Bertram F., Bendefeldt E., Otto H., Dtsch. med. Wschr., 1956, Bd. 81, S. 274.
27. Boas E.
28. Bogdanowitz G. a. oth., Acta clin. belg., 1953, vol. 8, page 585.
29. Boulin R., Presse med., 1956, vol. 64, page 643.
30. Bryfogle J. W., Bradley R. F., Diabetes, 1957, vol. 6, page 159.
31. Chatagnon C., Chatagnon P., Ann. biol. clin., 1958, vol. 16, page 233.
32. Christiansson J., Acta ophth., 1958, vol. 36, page 141.
33. Cugudda E. a. oth., Atti Accad. fisiocr. Siena, sez. med. fis., 1956, vol. 3, page XVIII.
34. Danowski T. S., Diabetes mellitus. Baltimore, 1957.
35. Del Vecchio A. a. oth., Endocrinol. esc. cost., 1957, vol. 24, page 93.
36. Dickinson L., J. Kentucky M. A., 1955, vol. 55, page 894.
37. Emmrich R., Das Bluteiweisbild. Diagnose und Therapie der Bluteiweisstorungen. Stuttgart, 1957.
38. Feruglio F., Rimini R., Omnia med., 1956, vol. 34, page 351.
39. Furman R. H., Howard F. P., Ann. Intern. Med., 1957, vol.

47, page 969.

40. Galletti F. a. oth., Arch. stud. fisiopat. ricambio, 1956, vol. 20, page 205.

41. Idem. Arch. pat. e clin. med., 1956, vol. 32, page 269.

42. Idem. Minerva Med., 1956, vol. 2, page 582.

43. Gilliland I. C. a. oth., Biochem. J., 1956, vol. 56, page XXXII.

44. Grassmann u. Hanning. UNT. F. Wuhrman, Ch. Wunderly.

45. Introzzi P. a. oth., Acta med. scandinav., 1958, vol. 160, page 47.

46. Jacobs H. R., J. Lab. clin. med., 1949, vol. 34, page 116.

47. Joslin E. P., The treatment of diabetes mellitus. Philadelphia, 1944, page 420.

48. Kaeding A., Diabetes Komplikationen. Stuttgart, 1956.

49. Kuhne P., Schultz G. W., Arztl. Wshcr., 1957, Bd. 12, S. 112.

50. Lederer J. a. oth., Diabete, 1957, vol. 5, page 226.

51. Lerman S. a. oth., Arch. Ophth., 1957, vol. 57, page 354.

52. Lewis L. a. oth., J. Clin. Endocrinol., 1944, vol. 4, page 535.

53. Lewis, L., a. oth. Am. J. Med., Sc., 1947, v. 213, p. 214.

54. Lowy, A. D., Barach, J. H., Hrubec, Z., Diabetes, 1957, v. 6. p. 342.

55. Lowy, A. D., Barach, J. H. Circulation, 1958, v. 17, p.p. 14.

56. Matthews, J.D., Lancet, 1954, v. 2, p. 573.

57. Mellingoff, K., Klin. Wschr., 1951, Bd. 29, S. 708.

58. Moschcowitz, E., Ann. Intern. Med., 1951, v. 34, p. 1137.

59. Mohnike, G.,

60. Muting, D., Klin. Wschr., 1956, Bd. 34, S. 919.

61. Nervi, C., De Petra, Arch. stud. fisiopath. ricambio. 1956, v. 20, p. 217.

62. Nichols, N., a. oth. , Diabetes, 1956, v. 5, p. 468.

63. Nielsen, G. H., Poulsen, J. E., Danish M. Bull., 1954, v. 1, p. 70.

64. Orabona, M., a. oth., Arch. stud. fisiopat. ricambio, 1956.

65. Paschkis, K. E., a. oth., Clinical Endocrinology, New York, 1958.

66. Peterson, R. D., Beatty, C. H., Am. J. Physiol., 1958, v. 193, p. 79.

67. Polosa, P., Motta, L., Arch. stud. fisiopat. ricambio, 1956, v. 20, p. 220.

68. Ralli, E. P., a. oth. Metabolism, 1957, v. 6, p. 331.

69. Raynaud, R., a. oth., Bull. et mem. Soc. med. hop. Paris, 1953, v. 69, p. 394.

70. Riva, G., Das Serumweißbild, Bern., 1957.
71. Sandor, G., Sang, 1956, v. 27, p. 597.
72. Schertenleib, F., Tuller, E. F., Diabetes, 1958, v. 7, p. 46.
73. Scheurlen, P. G., Klin. Wschr., 1955, Bd. 33, S. 198.
74. Skouby, A., Acta med. scandinav., 1956, supp. 317, p. 1
75. Tolomelli, E., a. oth., Arch. stud. fisiopat. ricambio, 1956, v. 20, p. 196.
76. Vannini, P., a. oth., Arch. E. Maragliano, 1956, v. 12, p. 713.
77. Vannini, P., Tolomelli, E., a. oth., Minerva med., 1956, v. 2, p. 580.
78. Voigt, K.D., Schrader, E. A., Klin., Wishr., 1955, Bd. 33, S. 465.
79. Warren, S., Le Compte, P. M., Pathology of Diabetes Mellitus, Philadelphia, 1952.
80. Weicker, H., Lau, H., Arztl. Wschr., 1956, Bd. 11, S. 29.
81. Wenderoth, H., Dtsch. Ztschr., Verdaunngs, Kr., 1955, Bd. 15, s. 222.
82. Wuhrman, F., Wunderly, Ch., Die Bluteiweißkörper der Menschen Basel - Stuttgart, 1957.

END